Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine

– Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease – – Presentation at the 12th International Symposium on Pneumococci and Pneumococcal Diseases – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of … [Read more…]

PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform

GC 2400 solution streamlines performance and delivers superior precision for high throughput environments WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the GC 2400™ Platform, an advanced, automated gas chromatography (GC), headspace sampler and GC/mass spectrometry (GC/MS) solution designed to help lab teams simplify lab … [Read more…]

BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and … [Read more…]

Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

New Drug Application filing anticipated based on positive data from interim analysis WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a statistically … [Read more…]

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

– Carbon is developing a novel parvovirus-based vector platform with demonstrated in-vivo tissue specificity, increased cargo capacity, and minimal natural neutralizing immunity; widens patient applicability and may enable gene therapy re-administration – Carbon’s lead candidate, CGT-001, targets lung tissue with demonstrated upper airway tissue tropism and repeatable dosing in gold-standard cystic fibrosis models – Financing … [Read more…]

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions at Analytica 2022

MUNICH–(BUSINESS WIRE)–$BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022. Frank H. Laukien, PhD, President and CEO of Bruker Corporation, commented: “Our differentiated high-value scientific instruments and … [Read more…]

Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis

Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation today announced its investment of $6 million in Carbon Biosciences to support the company‘s preclinical research into an innovative … [Read more…]

Humanetics Acquires mg-sensor to Advance Its Safety, Digital and Sensor Vision

FARMINGTON HILLS, Mich.–(BUSINESS WIRE)–Humanetics announced today that mg-sensor GmbH, specialists in the design and development of high-quality sensors, data acquisition and calibration services, is officially joining the Humanetics group. This partnership is another milestone as Humanetics brings to life its vision to provide fully integrated solutions with hardware, software, IoT and sensor technologies, that will … [Read more…]

Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures

CLEVELAND, Ohio–(BUSINESS WIRE)–$ATHX–Athersys, Inc. (Nasdaq: ATHX) today announced the Company’s slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET. As previously announced, in connection with the Company’s cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from ten to … [Read more…]

Edwards Lifesciences’ Unifying Generations Report Seeks to Transform Perceptions of the “Pivotal” 3rd Generation

Survey of 12,850 people demonstrates the significant contribution of over-65s; report makes three-point recommendations to further improve intergenerational solidarity. NYON, Switzerland–(BUSINESS WIRE)–Edwards Lifesciences today published ‘Unifying Generations: Building the Pathway to Intergenerational Solidarity’ – a report, based on a survey of 12,850 Europeans across generations, that demonstrates the need to change perceptions of the value … [Read more…]